A Phase I/II trial of radiotherapy concurrent with TS-1 plus cisplatin in patients with clinically resectable type 4 or large type 3 gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1205.
|
| Abstract |
A Phase I/II trial of radiotherapy administered concurrently with TS-1 plus cisplatin has been initiated in Japanese patients with clinical resectable type 4 or large type 3 gastric cancer. The aim of this trial is to determine the recommended dose of TS-1 and cisplatin combined with radiotherapy at a fixed dose in the Phase I study, and to evaluate the efficacy and safety in the Phase II study. The primary endpoint for Phase II is the pathological complete response rate, assessed using surgically resected specimens. Secondary endpoints are the response rate, progression-free survival, overall survival, operation transitional rate, R0 resection rate, rate of treatment completion, rate of down-staging and rates of postoperative complications and adverse events. In Phase II, a total of 30 patients will be enrolled in the Osaka Gastrointestinal Cancer Chemotherapy Study Group trial over a period of 6 years.
|
|---|---|
| Authors | Motohiro Imano, Hiroshi Furukawa, Masaki Yokokawa, Yasumasa Nishimura, Yukinori Kurokawa, Taroh Satoh, Daisuke Sakai, Takushi Yasuda, Haruhiko Imamoto, Toshimasa Tujinaka, Toshio Shimokawa, Hitoshi Shiozaki, Osaka Gastrointestinal Cancer Chemotherapy Study Group |
| Journal | Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 43 Issue 4 Pg. 431-5 (Apr 2013) ISSN: 1465-3621 [Electronic] England |
| PMID | 23447812 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!